CureVac – Talk Bio

Actionable Insights Powered by AI

BioNTech Acquires CureVac to Advance mRNA Cancer Therapies and End Patent Disputes

1 month ago talkbio0Tagged Acquisition, BioNTech, biotech merger, COVID19 (disease), CureVac, Immunotherapy for cancer, Legal patent, Merger, RNA, Messenger, Vaccines

BioNTech; CureVac; mRNA; acquisition; COVID-19 vaccine; cancer immunotherapy; merger; patent dispute; biotech merger

BioNTech to Acquire CureVac in $1.25B All-Stock mRNA Deal

1 month ago talkbio0Tagged Acquisition, all-stock, BioNTech, Biotechnology, Cancer Therapeutic Procedure, COVID-19 Vaccines, CureVac, Germany, mRNA Vaccines, Neoplasms

BioNTech; CureVac; acquisition; mRNA vaccines; cancer treatment; all-stock deal; Germany; biotechnology; oncology; COVID-19 vaccine

Biopharma Layoff Tracker 2024: CureVac, Takeda, Aerovate and More Cut Staff

1 year ago talkbio0Tagged 2024, Aerovate, Biopharma, CureVac, Industry, layoffs, Takeda, trends qualifier

Biopharma, Layoffs, 2024, CureVac, Takeda, Aerovate, Job Cuts, Industry Trends

Enhanced Optimization for Influenza B Strains Planned in CureVac’s mRNA Seasonal Flu Vaccine Trials

1 year ago talkbio0Tagged cellular targeting, Collaboration, CureVac, Immune response, Improved, influenza B strains, mRNA flu, Optimization, Vaccines

CureVac, mRNA flu vaccine, Influenza B strains, Targeted optimization, Phase 2 studies, Multivalent candidate, Improved immune response, Collaboration with GSK